MetLife Inc. (NYSE: MET) recommended shareholders reject an unsolicited mini-tender offer from Potemkin Limited to purchase up to 100,000 shares of MetLife common stock. The offer represents approximately 0.02 percent of MetLife's outstanding shares as of March 31, 2026.

Potemkin's offer price of $44.20 per share is approximately 41.35 percent below MetLife's closing price of $75.36 on April 13, 2026, according to the company's statement.

"MetLife does not endorse Potemkin's unsolicited mini-tender offer and recommends that shareholders do not tender their shares in response to Potemkin's offer because the offer is at a price that is significantly below the current market value of MetLife's common stock," the company stated.

MetLife emphasized it has no association with Potemkin or its offer. The company noted that mini-tender offers, which seek to acquire less than five percent of outstanding shares, avoid many Securities and Exchange Commission disclosure and procedural requirements that apply to larger tender offers.

The SEC has previously cautioned investors about mini-tender offers at below-market prices, stating that some bidders hope to "catch investors off guard if the investors do not compare the offer price to the current market price."

MetLife advised shareholders who have not responded to take no action. Those who have already tendered shares may withdraw them before the offer expires on March 26, 2027, at 5 p.m. Eastern time, according to the terms outlined in Potemkin's offer documents.

The company noted that Potemkin has made similar mini-tender offers for shares of other companies. MetLife urged investors to obtain current market quotations and consult with brokers or financial advisors regarding the offer.